Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Carcinoma 1

Interventions

Cisplatin 12pembrolizumab 11Magnetic Resonance Spectroscopy 11Specimen Handling 10Paclitaxel 6Platinum 5Cyclophosphamide 51,2-diaminocyclohexaneplatinum II citrate 5fludarabine 4durvalumab 4cemiplimab 4Radiotherapy, Intensity-Modulated 4Radiotherapy 3Pemetrexed 3Oxaliplatin 3Nivolumab 3Fluorouracil 3Cetuximab 3Carboplatin 3Biopsy 3poly ICLC 2fludarabine phosphate 2cabozantinib 2atezolizumab 2Radiation 2Ipilimumab 2Interviews as Topic 2Heavy Ion Radiotherapy 2Gemcitabine 2Drug Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma × (225)Ac-DOTA-c(RGDyK) × Clear all
NCT06589804 2026-06-03

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

National Cancer Institute (NCI)

Phase 3 Recruiting
158 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡